Jefferies analyst Brian Abrahams reiterated a Buy rating and boosted his price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $3.00 (from $2.50).

Abrahams commented, "Though it has taken some time for ganaxolone to find its optimal indications, based on its GABA mechanism, and promising data from SAGE's similar drug allopregnanolone, we continue to believe MRNS's program has good LT promise. With potential initial EEG data for IV ganaxolone in 1H17 and announcement of a strategy in female depression disorders expected 2H16, we see catalysts to drive near-term appreciation."

For an analyst ratings summary and ratings history on Marinus Pharmaceuticals click here. For more ratings news on Marinus Pharmaceuticals click here.

Shares of Marinus Pharmaceuticals closed at $1.45 yesterday.